Publication | Closed Access

Trastuzumab (Herceptin®) plus docetaxel versus docetaxel alone as first-line treatment of HER2-positive metastatic breast cancer (MBC): results of a randomised multicentre trial

Breast OncologyOncologyPharmacologyClinical TrialsDocetaxel Versus DocetaxelBreast CancerPharmacotherapyFirst-line TreatmentCancer TreatmentMedicineRandomised Multicentre Trial